Home » Topics » BioWorld Science, Endocrine/metabolic

BioWorld Science, Endocrine/metabolic
RSS

Amglidia recommended for E.U. approval for neonatal diabetes

Feb. 26, 2018

EC first to approve Crysvita for treatment of X-linked hypophosphatemia

Feb. 26, 2018

Corcept announces interim phase II results for relacorilant in patients with hypercortisolism

Feb. 23, 2018

Novo Nordisk reports topline results from PIONEER 1 trial of oral semaglutide in type 2 diabetes

Feb. 23, 2018

Frequency Therapeutics receives grant from JDRF

Feb. 23, 2018

FDA grants priority review to lanadelumab BLA for HAE

Feb. 23, 2018

AbbVie announces topline results from phase III trial of elagolix for uterine fibroids

Feb. 22, 2018

Soleno Therapeutics completes end-of-phase II meeting for diazoxide choline controlled-release

Feb. 21, 2018

Sunshine Lake Pharma identifies new farnesoid X receptor agonists

Feb. 21, 2018

Cincera Therapeutics launches with aim of treating diseases associated with obesity

Feb. 19, 2018

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 15, 2026.
MMP inhibitors divulged in Accure Therapeutics patent
BioWorld Science
Accure Therapeutics has reported new oligopeptide derivatives acting as matrix metalloproteinase-2 (MMP-2) and MMP-9 inhibitors. As such, they are described as...
News in brief
BioWorld Asia
BioWorld Asia briefs for April 14, 2026
Selective CBL-B inhibitor with improved safety profile disclosed
BioWorld Science
CBL-B is a RING-type E3 ubiquitin ligase that acts as a negative regulator of T-cell activation, contributing to immune homeostasis by limiting excessive immune...
MSD discloses new HCN1/2 blockers
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has synthesized new indazole derivatives acting as potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 1...